Increasing Volume Of Essential Clinical Supplies To Patients In Their Homes As Part Of Ongoing Response To COVID-19

Current situation and evolving

Covid-19 poses an unprecedented threat to the continuity of supply of vital medications to patients enrolled in clinical trials around the world. To rise to the rapidly developing clinical supply chain challenges caused by this global pandemic, sponsors are reviewing protocols, seeking expert guidance from their Contract Development and Manufacturing Organisation (CDMO) and acting with agility implementing necessary strategic actions. Quarantines, travel restrictions, site closures and limited site personnel are some of the factors contributing to this increased level of risk, which is presenting unprecedented challenges to those tasked with delivering the right drug to patients, at the right time and at the right temperature. Almac and its sponsors are working closely to ensure patients receive their treatments amidst changing circumstances and increasing restrictions. Delays are not an option and it is mission critical for Almac to deliver for patients, a shared objective with its sponsors.